10 free, board-style Psychiatry/Behavioral questions for the PANRE, each with the correct answer and a complete explanation. No email, no account required.
Psychiatry/Behavioral is 7% of the PANRE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.
Question 1PsychiatryMedium
A 22-year-old man has 3 weeks of decreased need for sleep, grandiosity, pressured speech, and excessive goal-directed activity, and he recently spent $50,000 on cryptocurrency. This is his first such episode. Urine toxicology is negative. Which of the following is the most likely diagnosis?
ABipolar II, hypomanic episode
BBipolar I, manic episode
CSchizophrenia
DBorderline personality disorder
ESchizoaffective disorder
Reveal answer & full explanation
Correct answer: B — Bipolar I, manic episode
ABipolar II, hypomanic episode
BBipolar I, manic episode✓
CSchizophrenia
DBorderline personality disorder
ESchizoaffective disorder
Why Bipolar I, manic episode is correct
A sustained period (here 3 weeks, well beyond the 1-week threshold) of decreased need for sleep, grandiosity, pressured speech, increased goal-directed activity, and impulsive spending meets criteria for a manic episode.
A single manic episode is sufficient to diagnose bipolar I disorder, regardless of any prior depression.
Acute mania is treated with a second-generation antipsychotic, lithium, or valproate; antidepressant monotherapy is avoided because it can precipitate mania or cycling.
Why the others are wrong
Schizophrenia — a primarily psychotic disorder; this presentation is a discrete mood episode with classic manic features rather than chronic psychosis. Sets the confused-with-psychosis trap.
Schizoaffective disorder — requires at least 2 weeks of delusions or hallucinations while no major mood episode is present; this man reports no psychotic symptoms at all, let alone any outside the mood episode. Sets the mood-plus-psychosis trap.
Borderline personality disorder — impulsive spending and mood shifts occur, but its affective instability lasts hours to a few days, is reactive to interpersonal stress, and is a lifelong trait pattern rather than a discrete 3-week episode with decreased need for sleep. Sets the impulsivity-equals-mania trap.
Bipolar II, hypomanic episode — hypomania shares these symptoms, but by definition it is not severe enough to cause marked impairment, and bipolar II also requires at least one major depressive episode, which is not described; reckless spending of $50,000 over a 3-week episode signals the marked impairment of mania, which defines bipolar I. Sets the mania-versus-hypomania trap.
Question 2PsychiatryMedium
A 55-year-old man with severe alcohol use disorder completes medically supervised detoxification during a hospitalization. He is motivated to remain abstinent but reports strong daily cravings for alcohol. He takes no opioid medications and has no history of opioid use disorder. Which of the following medications is most appropriate to reduce his alcohol cravings?
ABupropion
BDisulfiram
CNaltrexone
DLorazepam
ESertraline
Reveal answer & full explanation
Correct answer: C — Naltrexone
ABupropion
BDisulfiram
CNaltrexone✓
DLorazepam
ESertraline
Why Naltrexone is correct
Naltrexone is a mu-opioid receptor antagonist that blunts the rewarding effect of alcohol and directly reduces craving, which is exactly what this patient reports
It is a first-line anti-craving agent for alcohol use disorder per current APA and VA/DoD guidance and is a strong fit once detoxification is complete
It can be started while a patient is still drinking and does not require prior abstinence, unlike disulfiram
A monthly long-acting injectable formulation is available to support adherence; the stem confirms no opioid use, so there is no risk of precipitating opioid withdrawal
Why the others are wrong
Lorazepam — A benzodiazepine used for acute alcohol withdrawal (CIWA-guided), not relapse prevention; choosing it confuses the withdrawal phase, which is already complete, with ongoing craving reduction (right-drug-wrong-phase).
Disulfiram — Works by aversion (acetaldehyde accumulation causing flushing and nausea if alcohol is ingested) and deters drinking through fear of the reaction; it does not reduce craving as the lead-in specifically requires (buzzword-matching on 'alcohol use disorder').
Sertraline — An SSRI that treats comorbid depression or anxiety but has no established effect on craving or drinking outcomes in alcohol use disorder, so it targets the wrong problem for this lead-in (treating the comorbidity instead of the craving).
Bupropion — An antidepressant that reduces nicotine craving and withdrawal in smoking cessation, which makes it look like a general anti-craving drug, but it has no established benefit for alcohol craving or drinking outcomes in alcohol use disorder, and it lowers the seizure threshold, a concern soon after alcohol withdrawal (right-drug-wrong-substance).
Question 3PsychiatryMedium
A 25-year-old male has a first episode of psychosis with auditory hallucinations, paranoid delusions, disorganized speech, and flat affect for 3 months. He uses cannabis. Brain MRI and labs are normal. He is started on risperidone. Which of the following pharmacologic strategies is most likely to reduce his risk of psychotic relapse?
AIntermittent antipsychotic dosing
BLong-acting injectable antipsychotic
CTwo concurrent oral antipsychotics
DContinued oral antipsychotic
EGuided antipsychotic dose reduction
Reveal answer & full explanation
Correct answer: B — Long-acting injectable antipsychotic
AIntermittent antipsychotic dosing
BLong-acting injectable antipsychotic✓
CTwo concurrent oral antipsychotics
DContinued oral antipsychotic
EGuided antipsychotic dose reduction
Why Long-acting injectable antipsychotic is correct
Medication non-adherence is the biggest driver of relapse in first-episode psychosis (FEP) — over 50% relapse within 5 years
Long-acting injectable (LAI) antipsychotics (aripiprazole lauroxil, paliperidone palmitate, risperidone microspheres) lower relapse and hospitalization compared with oral antipsychotics across randomized trials (pooled risk ratio about 0.88), with larger effects in mirror-image and real-world studies
After a first episode of schizophrenia, a randomized trial found far fewer relapses with LAI risperidone than with oral risperidone over 12 months (5% vs 33%; Subotnik 2015)
Why the others are wrong
Continued oral antipsychotic — continuous oral maintenance clearly lowers relapse compared with placebo or discontinuation, but partial or covert nonadherence is common after a first episode, especially with ongoing cannabis use, and LAIs lower relapse further than oral dosing in randomized trials
Two concurrent oral antipsychotics — antipsychotic polypharmacy is not recommended; does not improve outcomes and increases side effects
Intermittent antipsychotic dosing — randomized trials of prodrome-triggered intermittent treatment show higher relapse and rehospitalization rates than continuous maintenance therapy
Guided antipsychotic dose reduction — tempting because long-term follow-up of a first-episode trial linked early dose reduction with better functional recovery, but randomized trials of tapering or discontinuing antipsychotics after a first episode show more relapses than continuous maintenance treatment, so it raises rather than lowers his relapse risk
Additional high-yield points
Coordinated specialty care for FEP improves employment, school functioning, and symptoms, and reduces hospitalization
Treatment duration: minimum 1-2 years after first episode, often lifelong
Question 4PsychiatryMedium
A 70-year-old man with moderate Alzheimer dementia who takes donepezil is seen in clinic with his daughter. Over the past 6 weeks, he has had frightening visual hallucinations and severe agitation at night, and he has struck his daughter twice. A consistent daily routine, daytime activity and light exposure, and caregiver redirection have not helped. On examination, he is calm and afebrile and shows no sign of pain; he is alert, his attention is at baseline, and there is no rigidity or tremor. A medication review finds no offending drug, and urinalysis, complete blood count, and basic metabolic panel are normal. His daughter asks about medication for the hallucinations and nighttime agitation. Which of the following medications is most appropriate?
ATrazodone
BDiphenhydramine
CQuetiapine
DHaloperidol
ELorazepam
Reveal answer & full explanation
Correct answer: C — Quetiapine
ATrazodone
BDiphenhydramine
CQuetiapine✓
DHaloperidol
ELorazepam
Why Quetiapine is correct
His hallucinations and agitation are dangerous, persist despite weeks of consistent nonpharmacologic measures, and occur without delirium or another reversible cause: the preconditions for an antipsychotic in dementia (APA 2016; AGS Beers 2023).
Because APA 2016 recommends against first-line haloperidol for nonemergency treatment without delirium, a low-dose second-generation antipsychotic is the choice among these options.
Quetiapine started low at bedtime (e.g., 12.5-25 mg) is sedating for nighttime symptoms and has minimal extrapyramidal effects; its low D2 affinity also makes it less likely than haloperidol to provoke neuroleptic sensitivity if Lewy body co-pathology underlies the visual hallucinations.
Its efficacy evidence is limited: APA 2016 found insufficient evidence for quetiapine and modest evidence for risperidone, olanzapine, and aripiprazole.
All antipsychotics, typical and atypical, carry an FDA boxed warning of 1.6-1.7x increased mortality from CV events and pneumonia in elderly patients with dementia; obtain informed consent, use the lowest effective dose, reassess regularly, and use the shortest course possible (taper off if there is no response after a 4-week trial; if he responds, attempt a taper within 4 months, per APA 2016).
Why the others are wrong
Lorazepam — benzodiazepines increase fall risk, worsen cognitive impairment, and cause paradoxical agitation in elderly patients with dementia, and they do not treat hallucinations; AGS Beers 2023 advises avoiding them in older adults and in dementia.
Haloperidol — the "hallucinations plus severe agitation" reflex fits hyperactive delirium or an acute emergency, where short-term low-dose haloperidol can be appropriate, but for nonemergency treatment without delirium APA 2016 recommends against it as a first-line agent. The boxed warning is shared but the risk is not: it causes more extrapyramidal effects and falls, carries excess mortality at least as high as any atypical studied and about twice quetiapine's (Maust, JAMA Psychiatry 2015), and can provoke severe neuroleptic sensitivity if Lewy body pathology is present.
Diphenhydramine — a first-generation antihistamine with strong anticholinergic effects; causes confusion, urinary retention, and worsened cognitive impairment in elderly patients, and directly opposes his donepezil; listed on the AGS Beers Criteria as potentially inappropriate (avoid).
Trazodone — a sedating antidepressant often used off-label for sleep and sundowning in dementia, but it has no antipsychotic effect on his frightening hallucinations, its evidence even for sleep in dementia is limited, and its orthostatic hypotension adds to fall risk.
Additional high-yield points
The FDA-approved drugs for agitation associated with Alzheimer dementia are brexpiprazole (2023) and dextromethorphan-bupropion (2026); both are approved for agitation, not psychosis.
Pimavanserin (Nuplazid) is FDA-approved (2016) only for hallucinations and delusions of Parkinson disease psychosis; FDA declined the dementia-related psychosis (2021) and Alzheimer disease psychosis (2022) indications.
For irregular sleep-wake rhythm in dementia, AASM 2015 suggests light therapy, suggests avoiding melatonin, and recommends against sleep-promoting drugs; Cochrane 2020 found no benefit from melatonin in Alzheimer dementia and only limited evidence for low-dose trazodone or suvorexant.
Question 5PsychiatryMedium
A 28-year-old woman presents with five months of mood swings, irritability, tearfulness, and difficulty concentrating that occur in the week before menses and resolve within a few days of menstrual onset. She charts her symptoms prospectively for two consecutive cycles and reports symptom-free intervals during the follicular phase. The symptoms cause significant impairment at work and strain her marriage. Her medical history and physical exam are unremarkable. Which of the following is the most appropriate first-line pharmacologic therapy?
ALithium
BBupropion
CSertraline
DAlprazolam
EProgesterone
Reveal answer & full explanation
Correct answer: C — Sertraline
ALithium
BBupropion
CSertraline✓
DAlprazolam
EProgesterone
Why Sertraline is correct
This patient meets DSM-5 criteria for premenstrual dysphoric disorder (PMDD): affective and somatic symptoms confined to the luteal phase, prospectively confirmed across at least two cycles, with full remission shortly after menses and clinically significant impairment
SSRIs are first-line pharmacotherapy for PMDD; sertraline, fluoxetine, paroxetine, and citalopram have the strongest evidence
SSRIs for PMDD can be dosed either continuously or only during the luteal phase, with onset of benefit within days rather than the weeks required for major depressive disorder
Why the others are wrong
Alprazolam — can blunt premenstrual anxiety but carries dependence and sedation risks and is not first-line for PMDD
Bupropion — lacks efficacy data for PMDD and is generally avoided because it does not address the serotonergic mechanism implicated in luteal-phase mood symptoms
Lithium — a mood stabilizer used for bipolar disorder; has no role in PMDD, which is a depressive-spectrum disorder confined to the luteal phase
Progesterone — the luteal-phase timing invites the idea of a progesterone deficiency, but PMDD reflects an abnormal response to normal cyclic hormone changes rather than low progesterone, and trials have not shown progesterone supplementation to outperform placebo
Question 6PsychiatryMedium
A 55-year-old male with post-traumatic stress disorder (PTSD) from combat has hypervigilance, flashbacks, avoidance of crowds, and nightmares for 8 years. He has tried sertraline for 2 years with only partial response. Which of the following psychotherapies has the strongest evidence for PTSD?
ASupportive expressive group psychotherapy
BInterpersonal social rhythm therapy
CDialectical behavior skills therapy
DTrauma-focused cognitive behavioral therapy
EExposure and response prevention therapy
Reveal answer & full explanation
Correct answer: D — Trauma-focused cognitive behavioral therapy
ASupportive expressive group psychotherapy
BInterpersonal social rhythm therapy
CDialectical behavior skills therapy
DTrauma-focused cognitive behavioral therapy✓
EExposure and response prevention therapy
Why Trauma-focused cognitive behavioral therapy is correct
Trauma-focused psychotherapies have the strongest evidence for post-traumatic stress disorder (PTSD).
Prolonged Exposure (PE): imaginal exposure (recounting the trauma repeatedly) plus in vivo exposure (real-world avoided situations) — reduces PTSD symptoms in 60-80% of patients.
Eye Movement Desensitization and Reprocessing (EMDR): bilateral stimulation during trauma memory processing.
Why the others are wrong
Supportive expressive group psychotherapy — lacks the trauma-focused exposure component that drives PTSD symptom reduction; not first-line (right-concept-wrong-modality).
Dialectical behavior skills therapy — first-line for borderline personality disorder and emotion dysregulation, not PTSD (premature closure).
Interpersonal social rhythm therapy — used in bipolar disorder to stabilize circadian rhythms; not indicated for PTSD (confused-with mood-disorder therapy).
Exposure and response prevention therapy — an exposure-based cognitive behavioral therapy, which makes it look interchangeable with prolonged exposure, but it is the first-line protocol for obsessive-compulsive disorder, pairing exposure to obsessional triggers with blocking compulsions rather than processing the trauma memory (confused-with OCD therapy).
Additional high-yield points
Pharmacotherapy: selective serotonin reuptake inhibitors (SSRIs) — sertraline and paroxetine are FDA-approved; serotonin-norepinephrine reuptake inhibitors (SNRIs) — venlafaxine.
Prazosin (alpha-1 blocker): reduces PTSD nightmares and sleep disturbance; evidence from multiple randomized controlled trials (RCTs); doses 1-15 mg at bedtime.
Benzodiazepines: AVOID in PTSD — worsen long-term outcomes, increase avoidance, and potentially worsen trauma processing.
Cannabis: growing interest but insufficient evidence; not recommended.
Question 7PsychiatryMedium
A 35-year-old female with schizophrenia has been stable on haloperidol for 2 years but developed tardive dyskinesia. Her psychiatrist wants to switch to an antipsychotic with the lowest tardive dyskinesia risk that is also effective for treatment-resistant schizophrenia. Which of the following agents is most appropriate?
AAripiprazole
BOlanzapine
CRisperidone
DQuetiapine
EClozapine
Reveal answer & full explanation
Correct answer: E — Clozapine
AAripiprazole
BOlanzapine
CRisperidone
DQuetiapine
EClozapine✓
Why Clozapine is correct
Clozapine has the lowest risk of extrapyramidal symptoms (EPS) and tardive dyskinesia of all antipsychotics.
Mechanism: weak D2 blockade (only 60-65%) with strong 5-HT2A antagonism plus H1, M1, and alpha-1 antagonism — accounts for low EPS risk.
It is the only antipsychotic FDA-approved for: (1) treatment-resistant schizophrenia (TRS — defined as failure of 2 adequate antipsychotic trials); and (2) reducing suicidal behavior in schizophrenia/schizoaffective disorder.
Why the others are wrong
Aripiprazole — a partial D2 agonist with low EPS risk, but not approved for treatment-resistant schizophrenia and lacks the clozapine evidence base for TRS (right-concept-wrong-drug).
Quetiapine — relatively low EPS risk, but not indicated for treatment-resistant schizophrenia (anchoring on low EPS alone).
Olanzapine — effective second-generation antipsychotic but carries significant metabolic side effects and is not preferred for TRS (premature closure).
Risperidone — a second-generation antipsychotic that may seem to share the low tardive dyskinesia risk of its class, but its potent, dose-dependent D2 blockade gives it among the highest EPS and tardive dyskinesia liability of the second-generation agents, and it is not indicated for treatment-resistant schizophrenia (assuming all second-generation agents are alike).
Additional high-yield points
Severe neutropenia (agranulocytosis) occurs in approximately 1% of patients on clozapine; absolute neutrophil count (ANC) is monitored per the prescribing information: weekly for 6 months, every 2 weeks for months 6-12, then monthly (the FDA eliminated the Clozapine REMS program in 2025).
Other clozapine side effects: weight gain, metabolic syndrome, myocarditis (early — monitor C-reactive protein (CRP) and troponin), seizures (dose-dependent), excessive salivation, constipation, orthostatic hypotension.
Vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine) treat established tardive dyskinesia (TD) in patients who remain on the offending antipsychotic.
Question 8PsychiatryMedium
A 45-year-old female with major depressive disorder (MDD) has been on sertraline 100 mg daily for 3 years with good response. She is planning to conceive and asks how to safely stop sertraline. Which of the following approaches is most appropriate?
AAlternate-day dosing then stop
BReplace sertraline with bupropion
CCross-taper to fluoxetine then stop
DTaper over three days then stop
EGradual taper over weeks to months
Reveal answer & full explanation
Correct answer: E — Gradual taper over weeks to months
AAlternate-day dosing then stop
BReplace sertraline with bupropion
CCross-taper to fluoxetine then stop
DTaper over three days then stop
EGradual taper over weeks to months✓
Why Gradual taper over weeks to months is correct
Abrupt or rapid discontinuation of sertraline precipitates SSRI discontinuation syndrome
SSRI discontinuation syndrome is remembered by the mnemonic FINISH: Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances (electric shock sensations/brain zaps), Hyperarousal and anxiety
Recommended tapering rate is approximately 10% per 2-4 weeks
Because she is not yet pregnant, the patient and provider have time to complete a proper gradual taper
Why the others are wrong
Cross-taper to fluoxetine then stop — fluoxetine's long half-life makes it a rescue strategy when withdrawal occurs, not a routine planned-pregnancy taper (confused-with the rescue indication)
Alternate-day dosing then stop — does not constitute a proper gradual taper and can itself precipitate withdrawal (right-concept-wrong-method)
Taper over three days then stop — three days after a 3-year course behaves like abrupt cessation and falls far short of the roughly 10% per 2-4 weeks reduction needed to avoid discontinuation syndrome (right-concept-wrong-duration)
Replace sertraline with bupropion — tempting because switching to another antidepressant seems to keep her covered while sertraline is withdrawn, but bupropion has no serotonergic activity, so it does not prevent SSRI discontinuation syndrome, and swapping drugs leaves her on a different antidepressant rather than completing the planned discontinuation (right-concept-wrong-drug)
Additional high-yield points
Paroxetine carries the highest discontinuation risk among SSRIs due to its short half-life (~21 hours) with no active metabolite, plus cholinergic rebound
Untreated depression during pregnancy carries risks including premature birth and postpartum depression; sertraline is among the most commonly used SSRIs in pregnancy
Question 9PsychiatryMedium
A 19-year-old woman has had a second suicide attempt, recurrent self-harm, intense fear of abandonment, unstable intense relationships, identity disturbance, and mood instability lasting hours rather than days. Which of the following is the most likely diagnosis?
AHistrionic personality disorder
BBipolar II disorder
CDependent personality disorder
DBorderline personality disorder
ERecurrent brief depression
Reveal answer & full explanation
Correct answer: D — Borderline personality disorder
AHistrionic personality disorder
BBipolar II disorder
CDependent personality disorder
DBorderline personality disorder✓
ERecurrent brief depression
Why Borderline personality disorder is correct
Borderline personality disorder (BPD) is diagnosed by 5 of 9 DSM-5 criteria: frantic efforts to avoid abandonment, unstable intense relationships, identity disturbance, impulsivity, recurrent self-harm, affective instability (mood swings lasting hours, reactive to interpersonal triggers), chronic emptiness, intense anger, and transient paranoia
This patient's abandonment fear, unstable relationships, identity disturbance, recurrent self-harm, and hours-long reactive mood instability fit the criteria
Lifetime completed suicide rate in BPD is 8-10%
Dialectical behavior therapy (DBT), developed by Marsha Linehan specifically for BPD, has RCT evidence for reducing self-harm, suicide attempts, ED visits, and hospitalizations and is the most effective psychotherapy
Why the others are wrong
Recurrent brief depression — describes short recurrent depressive episodes but does not account for the abandonment fear, identity disturbance, or self-harm pattern (confused-with mood disorder)
Histrionic personality disorder — features attention-seeking and shallow emotionality but lacks the recurrent self-harm, abandonment terror, and identity disturbance central to this case (right-cluster-wrong-disorder)
Bipolar II disorder — bipolar mood shifts last days to weeks and are autonomous, whereas this patient's shifts last hours and are reactive to interpersonal triggers (confused-with bipolar)
Dependent personality disorder — fear of being left alone is shared with BPD, but dependent personality disorder is a cluster C pattern of submissive, clinging reliance on others for reassurance and decisions, without the recurrent self-harm, identity disturbance, unstable intense relationships, and reactive mood instability described here (confused-with abandonment fear)
Question 10PsychiatryMedium
A 19-year-old man has 5 months of intrusive contamination fears and handwashing rituals that now consume 2-3 hours each day, which he acknowledges are excessive. The compulsions have caused him to drop out of college. He has never been treated. Which of the following initial treatment strategies has the strongest evidence base for his condition?
ASSRI plus clonazepam
BLow-dose olanzapine plus supportive counseling
CSupportive psychotherapy alone
DSSRI plus habit reversal training
ESSRI plus exposure and response prevention
Reveal answer & full explanation
Correct answer: E — SSRI plus exposure and response prevention
ASSRI plus clonazepam
BLow-dose olanzapine plus supportive counseling
CSupportive psychotherapy alone
DSSRI plus habit reversal training
ESSRI plus exposure and response prevention✓
Why SSRI plus exposure and response prevention is correct
This patient meets criteria for obsessive-compulsive disorder (OCD): time-consuming obsessions and compulsions he recognizes as excessive that impair functioning (dropped out of college)
The best-supported first-line treatment combines a selective serotonin reuptake inhibitor (SSRI) — often at higher doses than used for depression — with exposure and response prevention (ERP)
ERP is the specific cognitive-behavioral technique in which the patient is exposed to feared triggers while refraining from the compulsive ritual
Combined SSRI plus ERP is superior to either modality alone
Why the others are wrong
SSRI plus clonazepam — benzodiazepines do not treat the core obsessions and tend to reinforce avoidance, so they are not part of first-line OCD therapy (confused-with anxiety adjunct)
Low-dose olanzapine plus supportive counseling — antipsychotics are reserved as augmentation for refractory cases, not initial monotherapy in a treatment-naive patient (right-concept-wrong-step)
Supportive psychotherapy alone — generic counseling that omits exposure and response prevention lacks the active therapeutic ingredient for OCD (anchoring on nonspecific talk therapy)
SSRI plus habit reversal training — habit reversal training is first-line for trichotillomania and other body-focused repetitive behaviors in the obsessive-compulsive and related disorders group, and for tics, but it does not treat compulsions performed to neutralize obsessional fear; it lacks the exposure to contamination triggers with ritual prevention that defines ERP (confused-with trichotillomania therapy)
That's 10 of 7,700+. Get the rest.
Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
Are these Psychiatry/Behavioral PANRE practice questions free?
Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.
How much of the PANRE is Psychiatry/Behavioral?
Psychiatry/Behavioral makes up 7% of the PANRE content blueprint. FirstPassPA's timed PANRE exams are dealt to the same weights, so a practice exam carries the same share of Psychiatry/Behavioral questions.
How should I use these questions?
Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Psychiatry/Behavioral questions in the app, or take a full timed PANRE practice exam dealt to the blueprint weights.
Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.